

Claims

1. A compound of formula

(2S,4R)-4-[4-(5-Methyl-tetrazol-2-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide or a pharmaceutically acceptable salt or ester thereof.
5
2. A compound according to claim 1 for use as therapeutically active substance.
3. A pharmaceutical composition comprising a compound in accordance with claim 1 and a therapeutically inert carrier.
4. The use of a compound according to claim 1 for the preparation of medicaments for
10 the treatment or prophylaxis of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration.
5. A compound according to claim 1 for use in the treatment or prophylaxis of diabetes,
15 atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration.
6. A method for the treatment or prophylaxis of diabetes, atherosclerosis, abdominal
20 aortic aneurysm, peripheral arterial disease, cancer, reduction of cardiovascular events in chronic kidney disease, diabetic nephropathy, diabetic rethinopathy or age related macular degeneration, which method comprises administering an effective amount of a compound as defined in claim 1 to a patient in need thereof.
